Clovis Oncology Inc (NASDAQ:CLVS) – Equities researchers at SunTrust Banks issued their FY2022 earnings per share (EPS) estimates for shares of Clovis Oncology in a research note issued on Thursday. SunTrust Banks analyst P. Lawson anticipates that the biopharmaceutical company will post earnings per share of $10.84 for the year.
Several other analysts also recently issued reports on CLVS. Zacks Investment Research downgraded shares of Clovis Oncology from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. Oppenheimer reissued a “hold” rating on shares of Clovis Oncology in a research note on Tuesday, October 10th. Barclays started coverage on shares of Clovis Oncology in a research note on Monday, October 23rd. They set an “overweight” rating and a $105.00 target price on the stock. Morgan Stanley cut their target price on shares of Clovis Oncology from $89.00 to $86.00 and set an “overweight” rating on the stock in a research note on Thursday, November 2nd. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $125.00 price target on shares of Clovis Oncology in a research note on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $90.43.
Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.06). Clovis Oncology had a negative net margin of 947.47% and a negative return on equity of 122.06%. The company had revenue of $16.81 million for the quarter, compared to analyst estimates of $21.12 million. During the same quarter last year, the company posted ($1.70) EPS.
A number of institutional investors have recently bought and sold shares of CLVS. Capital Analysts LLC acquired a new position in Clovis Oncology during the third quarter worth $111,000. Phocas Financial Corp. acquired a new position in Clovis Oncology during the second quarter worth $112,000. Cypress Capital Management LLC WY increased its position in Clovis Oncology by 272.7% during the third quarter. Cypress Capital Management LLC WY now owns 2,050 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 1,500 shares during the last quarter. Commonwealth Equity Services Inc acquired a new position in Clovis Oncology during the third quarter worth $239,000. Finally, First Republic Investment Management Inc. acquired a new position in Clovis Oncology during the third quarter worth $251,000.
In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $59.16, for a total transaction of $177,480.00. Following the transaction, the insider now directly owns 183,571 shares of the company’s stock, valued at $10,860,060.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Thorlef Spickschen sold 4,500 shares of the stock in a transaction on Monday, January 8th. The stock was sold at an average price of $64.97, for a total transaction of $292,365.00. Following the transaction, the director now directly owns 21,118 shares in the company, valued at $1,372,036.46. The disclosure for this sale can be found here. Insiders sold 18,000 shares of company stock worth $1,123,425 over the last ninety days. 12.50% of the stock is currently owned by company insiders.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.